Advancing liver cancer treatment with dual-targeting CAR-T therapy

Advancing liver cancer treatment with dual-targeting CAR-T therapy

Abstract Chimeric antigen receptor (CAR)-T cell therapy targeting glypican-3 (GPC3) has shown promise in the treatment of hepatocellular carcinoma (HCC). However, the efficacy of CAR-T cells that focus solely on cell surface tumor-associated antigens is often limited. To overcome this challenge, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Ze Yang, Chao Cheng, Zhongliang Li, Huajing Wang, Mengmei Zhang, Ermin Xie, Xu He, Bing Liu, Hongwei Sun, Jiantao Wang, Xiaopei Li, Dingjie Liu, Xiaowen Lin, Xianyang Li, Ping Jiang, Ligong Lu, Xiaowen He, Meixiao Zhan, Ke He, Wei Zhao
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Journal of Nanobiotechnology
Subjects:
Liver cancer
Glypican-3
Alpha-fetoprotein
CAR-T
BiTE
Online Access:https://doi.org/10.1186/s12951-025-03512-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12951-025-03512-w

Similar Items